Terms: = Lung cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Clinical Outcome
9 results:
1. Discovery and characterization of novel peptide inhibitors of the nrf2/MAFG/DNA ternary complex for the treatment of cancer.
Simov V; Altman MD; Bianchi E; DelRizzo S; DiNunzio EN; Feng G; Goldenblatt P; Ingenito R; Johnson SA; Mansueto MS; Mayhood T; Mortison JD; Serebrov V; Sondey C; Sriraman V; Tucker TJ; Walji A; Wan H; Yue Y; Stoeck A; DiMauro EF
Eur J Med Chem; 2021 Nov; 224():113686. PubMed ID: 34303079
[TBL] [Abstract] [Full Text] [Related]
2. nfe2l2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved clinical outcome with Immunotherapy.
Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
[TBL] [Abstract] [Full Text] [Related]
3. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting nrf2 protein degradation.
Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
[No Abstract] [Full Text] [Related]
4. Elevated SRC3 expression predicts pemetrexed resistance in lung adenocarcinoma.
Chen Y; Sun Y; Zhao W; Ma Y; Yan Z; Nie X
Biomed Pharmacother; 2020 May; 125():109958. PubMed ID: 32036219
[TBL] [Abstract] [Full Text] [Related]
5. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression.
Shi Y; Fan S; Wu M; Zuo Z; Li X; Jiang L; Shen Q; Xu P; Zeng L; Zhou Y; Huang Y; Yang Z; Zhou J; Gao J; Zhou H; Xu S; Ji H; Shi P; Wu DD; Yang C; Chen Y
Nat Commun; 2019 Oct; 10(1):4892. PubMed ID: 31653849
[TBL] [Abstract] [Full Text] [Related]
6. Association between 18F-FDG uptake in PET/CT, nrf2, and NQO1 expression and their prognostic significance in non-small cell lung cancer.
Park SY; Lee SJ; Han JH; Koh YW
Neoplasma; 2019 Jul; 66(4):619-626. PubMed ID: 30868898
[TBL] [Abstract] [Full Text] [Related]
7. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract] [Full Text] [Related]
8. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival.
Qian Z; Zhou T; Gurguis CI; Xu X; Wen Q; Lv J; Fang F; Hecker L; Cress AE; Natarajan V; Jacobson JR; Zhang DD; Garcia JG; Wang T
Sci Rep; 2015 Nov; 5():16889. PubMed ID: 26596768
[TBL] [Abstract] [Full Text] [Related]
9. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
[TBL] [Abstract] [Full Text] [Related]
